Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension. Read why I'm ...
Mural nominated two new development candidates, MURA-8518 a novel binding protein-resistant IL-18 with half-life extension, ...
Medical Xpress on MSN10d
People who are immunocompromised may not produce enough protective antibodies against RSV after vaccinationScanning electron micrograph of human respiratory syncytial virus (RSV) virions (colorized blue) and tagged with antibodies ...
A new study conducted at the Scojen Institute for Synthetic Biology at Reichman University's Dina Recanati School of Medicine ...
News Medical on MSN2d
Novel hMPV strains linked to rising respiratory infections in young childrenResearchers in India discovered novel hMPV lineages A2.2.1 and A2.2.2, emphasizing their role in pediatric respiratory ...
Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm. Under the agreement, ...
Graft-Versus-Host disease market Insights. DelveInsight's Graft-Versus-Host Disease Market report offers an in-depth understanding of the epidemiology and ...
The recent findings of Waldo et al. 1 demonstrate that the fusion of the green fluorescent protein (GFP) to insoluble proteins dramatically reduces its folding ability in prokaryotic cells.
A replay of the event will be available for 90 days and can be accessed by visiting the “Investor Calendar” section of the Vera Therapeutics website.
It uses a ligand-dependent destabilization domain that is fused to a protein of interest. Addition of a membrane-permeant small molecule, Shield1, reversibly stabilizes the fusion protein in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback